Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein
The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.
1. A method for treating remyelination blockage in progressive Multiple Sclerosis (MS), comprising administering at least one anti-HERV-W Env antibody to a human in need thereof,
wherein the anti-HERV-W Env antibody comprises (i) a light chain variable region including each of the CDRs set forth in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, and (ii) a heavy chain variable region including each of the CDRs set forth in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6.
2. The method of claim 1 , wherein the anti-HERV-W Env antibody is a chimeric, engineered or humanized antibody.
3. The method of claim 1 , wherein the anti-HERV-W Env antibody is an IgG.
4. The method of claim 1 , wherein the anti-HERV-W Env antibody is an IgG1.
5. The method of claim 1 , wherein the anti-HERV-W Env antibody is an IgG4.
6. The method of claim 1 , wherein the progressive MS is Secondary Progressive MS (SPMS).
7. The method of claim 1 , wherein the progressive MS is Primary Progressive MS (PPMS).
8. A method of providing remyelination through oligodendrocyte precursor cell (OPC) differentiation, comprising administering an anti-HERV-W Env humanized monoclonal IgG4 antibody to a human in need thereof, wherein:
the human has progressive Multiple Sclerosis (MS); and
the anti-HERV-W Env humanized monoclonal IgG4 antibody comprises (i) a light chain variable region including each of the CDRs set forth in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, and (ii) a heavy chain variable region including each of the CDRs set forth in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6.
9. The method of claim 8 , wherein the human has Secondary Progressive MS (SPMS).
10. The method of claim 8 , wherein the human has Primary Progressive MS (PPMS).